--- title: MedTech Startup Failure Modes: 10 Reasons MedTech Startups Die description: The ten most common reasons MedTech startups die — each with the specific failure pattern Tibor and Felix have watched repeat across dozens of companies. authors: Tibor Zechmeister, Felix Lenhard category: MedTech Startup Strategy & PMF primary_keyword: MedTech startup failure modes canonical_url: https://zechmeister-solutions.com/en/blog/medtech-startup-failure-modes-10-reasons source: zechmeister-solutions.com license: All rights reserved. Content may be cited with attribution and a link to the canonical URL. --- # MedTech Startup Failure Modes: 10 Reasons MedTech Startups Die *By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.* > **MedTech startups rarely die from bad science. They die from ten repeating failure modes: ignoring MDR until forced, getting the intended purpose wrong, over-documenting from Day 1, budgeting two months for certification, hitting product-market fit with the wrong financing structure, signing a founder agreement that leaves 40% dead equity, taking an exclusivity clause in a term sheet, trusting a fake expert, assuming CE equals global market access, and treating CE marking as the finish line. Each failure mode below is a pattern Felix and Tibor have watched repeat across dozens of companies, with the specific regulatory or business consequence that kills the company.** **By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.** --- ## TL;DR - MedTech startups die from a small number of repeating failure modes, not from bad technology or bad luck. - The most expensive mode is ignoring MDR until a competitor sues or a customer asks for documentation that does not exist. - The second most expensive is getting the intended purpose wrong under MDR Article 2(12) and restarting the whole regulatory path months in. - Financing structure kills companies with perfect product-market fit. The capital has to match the cycle length of the business. - CE marking is not a finish line. It is the start of post-market obligations under MDR Articles 83 to 92 and the start of a different set of commercial problems. --- ## Why failure modes matter more than success stories The useful thing about failure modes is that they repeat. Success stories are idiosyncratic. The team, the moment, the market, the investor, the device, all have to line up. Failures converge on a small set of patterns. If you learn the patterns, you can avoid most of them without a mentor standing over your shoulder. Between them, Felix and Tibor have watched more than eighty MedTech startups up close over the past fifteen years. The ten failure modes below are the ones that show up again and again. Some of them are regulatory. Some are commercial. Some are legal. All of them are preventable. But only if you see the pattern before you are inside it. Each entry below names the failure mode, tells the story of a real company that died from it (anonymized), explains the mechanism, and points to the specific MDR article or business decision that makes it enforceable reality rather than opinion. --- ## 1. Ignoring MDR until forced The Vienna case is the one Tibor still thinks about. A startup with a solid Class IIa device, a real clinical need, a small team, and a plan to "deal with MDR later." The founders told themselves they would raise money first, get traction first, then hire a regulatory person once things were serious. Eighteen months in, a competitor filed an unfair competition suit based on non-compliant market placement. The court ordered the device off the market. The company had no technical file, no Notified Body engagement, no QMS, and no runway to build any of them while revenue was frozen. It went into bankruptcy inside a quarter. The mechanism is simple. Under MDR Article 5(1), no device may be placed on the market or put into service unless it complies with the Regulation. Market surveillance under Articles 93 to 100 is real, but as Tibor keeps telling founders: the most common trigger for enforcement is not an authority inspection. It is a competitor. Delaying MDR work is not a cost saving. It is a bet that nobody will notice, and the people most likely to notice are the people with the strongest incentive to report you. The rule is simple: if you cannot afford regulatory work, you cannot afford a MedTech project. Build the regulatory strategy into the founding plan or do a different business. --- ## 2. Wrong intended purpose. Classification restart A Graz wellness team spent nearly a year building toward Class I self-certification. Their positioning was "relaxation and wellbeing." Their actual pitch deck, their website copy, and their investor materials all described the product as addressing a specific clinical condition. Somewhere around month ten, during the intended purpose review, the mismatch surfaced. Under MDR Article 2(1), intended purpose is determined by the data supplied by the manufacturer on the label, in the instructions for use, and in promotional or sales materials. Their own marketing had placed the device squarely inside the medical device definition. The device was not Class I. It was Class IIa. The whole regulatory path had to restart. The mechanism here is that intended purpose under MDR Article 2(12) drives classification under Article 51 and Annex VIII, which drives conformity assessment under Article 52, which drives clinical evaluation requirements under Article 61. Every later decision cascades from this one. Get it wrong, and you are not editing a document. You are rebuilding a year of work. MDCG 2021-24 is the reference that walks through the classification rules in detail. The subtract-to-ship move is to get intended purpose right on Day 1, with expert input, before the rest of the work locks in. --- ## 3. Over-documenting from Day 1 The opposite failure mode is the one Felix and Tibor call "the company that could have shipped in 2020 and still is not on market in 2026." A Graz team decided to build a fully MDR-compliant QMS, a full Annex II technical file, and a complete risk management file before they had validated the product with a single user. Five years later, they have a beautiful documentation set, three pivots of a product that nobody asked for, and no revenue. The QMS is real. The device is not. The mechanism is that building a compliant QMS under EN ISO 13485:2016+A11:2021 for a product that has not been validated locks in assumptions that will change. Every pivot means rewriting half the QMS. The team ends up spending more time on documentation hygiene than on the thing that actually needs to get built, which is a product the market wants. The rule from [the Subtract to Ship framework](/blog/subtract-to-ship-framework-mdr) is: validate the problem and the market first, then build the QMS around the validated product. MDR does not require you to start bureaucracy before there is anything to bureaucratize. More documentation is not more quality. --- ## 4. Under-funded. The two-month MDR delusion Felix has met this founder at least six times in different cities. Brilliant engineer, working device, investor deck with a line item that reads something like "MDR certification: 2 months, EUR 40,000." Every single time, the real number is closer to twelve months and EUR 300,000 to 500,000 for a Class IIa device, and that is if nothing goes wrong. The fastest Class I certification Tibor has ever achieved from a standing start was about nine months. Class IIa and above routinely take twelve to eighteen months or more. The mechanism is that the founder has read a blog post or talked to someone who shipped a Class I device with no measuring function and no sterile components, and has assumed that timeline generalizes. It does not. Notified Body feedback alone averages seven to ten months in current capacity conditions. The founder raises a round based on the two-month number, runs out of money at month ten, and dies with a half-built technical file. The practical rule Felix gives every founder: estimate the real investment and time for MDR, then double it. If the doubled number breaks your financing plan, the financing plan was wrong. --- ## 5. Product-market fit without financing structure The shrimp farm taught Felix this one. Not a MedTech company, but the lesson transfers cleanly. A founder with a product that customers genuinely loved, a clear buyer, proven unit economics, and working operations. A textbook PMF case. What killed the company was the capital structure. The business cycle was long. The financing round was short. The investor terms assumed a software-style growth curve on a physical product with a twelve-month cycle. When the cycle stretched by two months for reasons outside anyone's control, the company could not bridge and the cap table collapsed. The MedTech version is the company that nails clinical validation, lines up hospitals, gets through MDR, and then dies because the reimbursement path takes eighteen months longer than the cash runway supports. Tibor has written about the Graz SaaS that passed MDR flawlessly and then watched reimbursement collapse the business model. Same pattern. PMF without the right financing structure is PMF on borrowed time. The rule: match your financing to your real business cycle, not to your pitch deck. For MedTech that usually means longer rounds, more conservative milestones, and honest conversations with investors about the gap between CE marking and revenue. See [MedTech fundraising stages](/blog/medtech-fundraising-stages) for how to plan the cash against the cycle. --- ## 6. 40% dead equity. The founder agreement failure Felix has a list of companies killed by their own cap table. The one that hurts the most is the team that gave a co-founder 40% equity with no vesting, no leaver clauses, and no performance conditions. The co-founder left after seven months for an unrelated reason, taking 40% of the company with them. Every subsequent investor conversation died on the same sentence: "We cannot invest in a cap table with that much dead equity." The company could not raise. The remaining founders burned out trying to bootstrap a MedTech business that needed six figures of regulatory investment they could not access. It wound down two years later. The mechanism is that founder equity without vesting is a permanent commitment to a transient decision. Vesting schedules, good-leaver / bad-leaver clauses, and founder agreements reviewed by a lawyer who has seen MedTech cap tables are not optional. They are the difference between a recoverable situation and a terminal one. The rule: never split founder equity without vesting. Ever. No exceptions for friends, family, or people who helped you early. A proper agreement protects both of you. --- ## 7. The exclusivity trap in fundraising Felix has watched this one burn three founders personally. An investor offers a term sheet with an exclusivity clause. Typically 60 to 90 days during which the startup cannot talk to other investors. The founder signs because the round feels urgent and the money feels close. The investor uses the exclusivity period to run extended due diligence, asks for changes, stretches the timeline, renegotiates terms, and either closes on worse terms than the original sheet or walks away at day 85. The founder emerges with no deal, no backup investors (because they are stale), and often no runway left to restart the process. The mechanism is simple: exclusivity transfers negotiating leverage from the founder to the investor for the duration of the clause. A founder in an exclusivity period cannot create competitive pressure. An investor who knows the founder has no alternatives has no incentive to move quickly or honor the original terms. The rule: do not sign exclusivity unless the clause is short, the price is fixed, and the deliverables are bounded. If an investor insists on a long open-ended exclusivity, walk. Good investors understand why. See [investor term sheets for MedTech founders](/blog/investor-term-sheets-medtech) for the specific clauses to watch. --- ## 8. The fake expert dependency A founder hires a "senior regulatory expert" based on a confident LinkedIn profile, a fluent first meeting, and the relief of finally having someone on the team who claims to know MDR. Six months later, the first real audit surfaces the truth: the expert has never actually built a technical file, has never sat through a Notified Body review, and has been learning on the job using the company's runway as tuition. Tibor has seen this at least four times in the past decade. One Austrian case: the founder lost nine months and a six-figure sum before realizing the PRRC they had hired under MDR Article 15 had no real experience with Annex II technical files or Annex VIII classification. The mechanism is that MDR expertise is asymmetric. A confident person with surface vocabulary sounds indistinguishable from a real expert to a founder who does not yet know the domain. The gap only surfaces under pressure. A Notified Body question, an auditor challenge, a non-conformity report. By which time months and money are gone. The rule is to verify claimed expertise before hiring. Ask for specific past projects, specific devices, specific Notified Body interactions. Ask who they worked with and check. Any real expert will welcome the questions. See [how to evaluate a regulatory consultant](/blog/evaluate-regulatory-consultant) for the specific questions that separate real from fake. --- ## 9. Assuming CE equals global market access A German startup passed MDR certification, got their CE mark, and started their international expansion. The US launch was planned for three months post-CE. The team had budgeted almost nothing for FDA work because their assumption was that CE certification would carry weight at the FDA. It did not. 510(k) is a different pathway with different evidence requirements. Their clinical data was not structured for an FDA submission. Their QMS was ISO 13485-based, which the FDA accepts in principle but expects to be linked to 21 CFR Part 820 compliance. The "three month" US launch became an eighteen-month FDA project they had not funded. The mechanism is that CE marking demonstrates compliance with Regulation (EU) 2017/745 under Article 20. It says nothing about FDA, ANVISA, TGA, PMDA, or any other regulator. Each market has its own evidence requirements, its own submission format, and its own timeline. Cross-recognition exists in limited forms for limited situations, but it is never automatic. The rule: if your business plan depends on global market access, budget each market separately. CE is the EU market. Nothing more. See [MDR versus FDA for startups](/blog/mdr-vs-fda-for-startups) for the structural differences that matter. --- ## 10. Treating CE marking as the finish line The last failure mode is the one that kills companies after they have apparently succeeded. A founder celebrates the CE certificate, the team takes a week off, and everyone assumes the hard work is done. Then the post-market obligations kick in: PMS system under MDR Article 83, PMS plan per Annex III, PMS report for Class I or PSUR for Class IIa and above, vigilance reporting under Articles 87 to 92, PMCF activities per Annex XIV Part B, and the next surveillance audit twelve months later. MDCG 2025-10 describes the full PMS system in detail. Plus the commercial problems: reimbursement, distribution, sales, and the gap between CE marking and actual revenue. The mechanism is that CE marking is the start of a second set of obligations and a second set of commercial problems, not the end of the first. Startups that budget "CE and then we ship" are surprised by both the cost and the duration of the post-market phase. The rule: plan the post-CE phase with the same seriousness as the pre-CE phase. Budget for PMS. Budget for the gap between CE and revenue. Budget for the surveillance audit. CE marking is the starting gun, not the finish line. --- ## The Subtract to Ship take on failure modes The useful framing is that nine of these ten failure modes are preventable at a specific, identifiable decision point. Ignoring MDR is prevented at the founding plan. Wrong intended purpose is prevented before the first MDR euro is spent. Over-documentation is prevented by sequencing. Validate first, document second. The two-month delusion is prevented by honest numbers. Financing-structure failure is prevented in the term sheet. Dead equity is prevented in the founder agreement. Exclusivity is prevented by reading the clause before signing. Fake experts are prevented by asking for specifics. Global-access confusion is prevented by budgeting each market separately. CE as finish line is prevented by planning the post-market phase. The tenth failure mode. The shrimp farm case. Is the one where nothing could have saved the company from its own capital structure. That one is a warning that getting the product right is necessary but not sufficient. The financing has to fit the business. The methodology here is the same as the rest of this blog: remove the wrong beliefs and wrong decisions that cause most failures, and the remaining decisions become much easier. Each of these ten modes is a removable belief or a removable decision error. --- ## Reality Check. Where do you stand? 1. For each of the ten failure modes above, can you state. Honestly. Whether your company is currently exposed to it? A vague "probably not" counts as a yes. 2. Which mode are you closest to right now? Be specific about the decision or assumption that creates the exposure. 3. Is there a decision in your next 30 days where one of these modes could flip from "potential" to "irreversible"? 4. Who on your team would push back on you if you were drifting into one of these? If nobody has the mandate to say no, the mandate needs to be created. 5. Which mode has the lowest cost to de-risk this week? Start there. 6. Have you budgeted MDR at the real number or at the pitch-deck number? If they are different, the gap is your exposure. 7. Does your founder agreement have vesting and leaver clauses? If you do not know, you do not have them. --- ## Frequently Asked Questions **What is the single most common way MedTech startups die?** Running out of money while waiting for MDR certification that was underestimated in both time and cost. This is the "two-month delusion" pattern. The founder budgets for a fraction of the real timeline, the round runs out at month ten or twelve, and the company dies with a half-built technical file. See failure mode 4. **Is MDR really the main reason MedTech startups fail?** No. MDR is the visible trigger in many cases, but the root cause is usually a decision made much earlier. Wrong intended purpose, wrong financing structure, wrong founder agreement, wrong assumption about what CE delivers. MDR is where the failure surfaces. The earlier decisions are where the failure was built. **How do I know if my intended purpose is right?** Read MDR Article 2(12) and Annex VIII classification rules, write your own intended purpose statement, classify the device yourself using MDCG 2021-24, and then have an experienced expert review both. If the expert's classification matches yours, you are probably right. If it does not, figure out who is wrong before you spend any more money. **Can a MedTech startup survive a 40% dead equity cap table?** Almost never at the investor stage. A few companies have bought out dead equity with revenue, but that requires a business that can generate cash without raising, which is rare in MedTech. The practical answer is: do not get there in the first place. Vesting and leaver clauses are non-negotiable. **Is it ever safe to sign an exclusivity clause in a term sheet?** Sometimes, if the clause is short (under 45 days), the price is fixed, the key terms are fixed, and the deliverables are bounded. Open-ended exclusivity with no fixed terms is a trap. If a serious investor insists on open-ended exclusivity and will not negotiate, that is information about how they will behave once they are on your cap table. **What should I do first if I think I am exposed to one of these failure modes?** Name it precisely. Write down which mode, which decision created the exposure, and what the cost is to reverse it. Reversing is almost always cheaper earlier than later. If reversing is not possible, then plan around the exposure honestly instead of hoping it resolves itself. --- ## Related reading - [15 MDR Myths That Waste Startup Time and Money](/blog/15-mdr-myths-that-waste-startup-time-and-money) – the belief set that leads to most of these failures. - [The No-Bullshit MDR Guide for First-Time Founders](/blog/no-bullshit-mdr-guide-first-time-founders) – the honest orientation for founders starting out. - [The Subtract to Ship Framework for MDR](/blog/subtract-to-ship-framework-mdr) – the methodology that prevents modes 3 and 4. - [Product-Market Fit for MedTech Startups](/blog/product-market-fit-medtech-startups) – the pillar post on getting PMF right before MDR spending starts. - [Why MedTech Startups Need Clinical Partners on Day 1](/blog/clinical-partners-day-one) – prevents the "18-month silence" pattern. - [MedTech Business Models That Actually Work](/blog/medtech-business-models-that-work) – prevents mode 5. - [How to Validate Your MedTech Idea Before Spending a Euro on MDR](/blog/validate-medtech-idea-before-mdr) – prevents modes 1, 3, and 4. - [MedTech Fundraising Stages and Realistic Milestones](/blog/medtech-fundraising-stages) – prevents modes 5 and 7. - [Investor Term Sheets for MedTech Founders](/blog/investor-term-sheets-medtech) – prevents mode 7. - [How to Build Your First MedTech Team Without Killing the Cap Table](/blog/first-medtech-team-cap-table) – prevents mode 6. --- ## Sources 1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Article 2(1) (definition of medical device), Article 2(12) (intended purpose), Article 5 (placing on the market), Article 10 (manufacturer obligations), Article 15 (PRRC), Article 20 (CE marking), Article 51 (classification), Article 52 (conformity assessment), Article 61 (clinical evaluation), Articles 83 to 86 (post-market surveillance), Articles 87 to 92 (vigilance), Articles 93 to 100 (market surveillance), Annex II (technical documentation), Annex III (PMS), Annex VIII (classification rules), Annex XIV (clinical evaluation and PMCF). Official Journal L 117, 5.5.2017. 2. Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices. 3. MDCG 2019-11 Rev.1 (June 2025). Guidance on Qualification and Classification of Software in Regulation (EU) 2017/745. MDR and Regulation (EU) 2017/746. IVDR. 4. MDCG 2021-24. Guidance on classification of medical devices, October 2021. 5. MDCG 2025-10. Guidance on post-market surveillance of medical devices and in vitro diagnostic medical devices, December 2025. 6. EN ISO 13485:2016 + A11:2021. Medical devices. Quality management systems. Requirements for regulatory purposes. --- *This post is part of the MedTech Startup Strategy and PMF series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. Every failure mode in this list is a pattern Felix and Tibor have watched repeat across real companies. Not a hypothetical. If you recognize your company in two or more of them, the useful next step is to name the exposure honestly and plan the de-risking. The earlier, the cheaper.* --- *This post is part of the [MedTech Startup Strategy & PMF](https://zechmeister-solutions.com/en/blog/category/startup-strategy) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*